Here are four things to know.
1. Shingrix is a nonlive, recombinant subunit Shingles vaccine for adults age 50 and older.
2. The vaccine is administered intramuscularly in two doses.
3. In a recent Phase III clinical trial with more than 38,000 patients, Shingrix had a more than 90 percent efficacy against shingles for all age groups.
4. GlaxoSmithKline expects Shingrix to be available shortly, pending a recommendation from the CDC’s Advisory Committee on Immunization Practices.
More articles on supply chain:
Analysis: Biosimilar drugs could cut US healthcare spending by $54B
Health apps should be held to high regulatory scrutiny, researchers say
FDA: 50 medical devices at risk of shortages after Hurricane Maria
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
